News | July 17, 2023
Evonik and Heraeus cooperate to expand the range of services for highly potent API
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The VITA-FAST tokens have been met with overwhelming interest
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Subscribe To Our Newsletter & Stay Updated
